PARADIGM-HF trial stopped early for benefit

The PARADIGM-HF trial has been stopped early for a benefit to patients that was overwhelmingly statistically significant. In the largest ever study of a heart failure treatment, LCZ696 won a head to head comparison with gold standard treatment and improved the primary composite endpoint of cardiovascular death or heart failure hospitalisation, and reduced cardiovascular mortality alone. Topics: Heart Failure (HF)
Source: ESC News and Press - Category: Cardiology Source Type: news